Kohei Nakachi

Summary

Affiliation: National Cancer Center
Country: Japan

Publications

  1. doi Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases
    Eiichiro Suzuki
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Oncology 79:39-45. 2010
  2. doi A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer
    Kohei Nakachi
    Division of Hepatobiliary, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, 277 8577, Japan
    Cancer Chemother Pharmacol 66:527-34. 2010
  3. ncbi Prognostic factors in patients with gemcitabine-refractory pancreatic cancer
    Kohei Nakachi
    Division of Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 37:114-20. 2007
  4. pmc Guidelines for chemotherapy of biliary tract and ampullary carcinomas
    Junji Furuse
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital East, Kashiwa shi, Chiba, Japan
    J Hepatobiliary Pancreat Surg 15:55-62. 2008
  5. ncbi [Chemotherapy]
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Gan To Kagaku Ryoho 37:408-12. 2010
  6. pmc Stenting and interventional radiology for obstructive jaundice in patients with unresectable biliary tract carcinomas
    Toshio Tsuyuguchi
    Department of Medicine and Clinical Oncology, Chiba University Graduate School of Medicine, Chiba, Japan
    J Hepatobiliary Pancreat Surg 15:69-73. 2008
  7. doi Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma
    Junji Furuse
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
    Cancer Sci 101:2606-11. 2010
  8. ncbi Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer
    Junji Furuse
    National Cancer Center Hospital East, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 36:552-6. 2006
  9. doi Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization
    Satoru Iwasa
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 41:770-5. 2011
  10. ncbi A phase I study of hypofractionated radiotherapy followed by systemic chemotherapy with full-dose gemcitabine in patients with unresectable locally advanced pancreatic cancer
    Junji Furuse
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Hepatogastroenterology 54:1575-8. 2007

Collaborators

Detail Information

Publications30

  1. doi Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases
    Eiichiro Suzuki
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Oncology 79:39-45. 2010
    ..The purpose of this study was to elucidate the treatment efficacy and safety of gemcitabine monotherapy, and to identify prognostic factors in patients with advanced biliary tract cancer receiving this therapy...
  2. doi A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer
    Kohei Nakachi
    Division of Hepatobiliary, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, 277 8577, Japan
    Cancer Chemother Pharmacol 66:527-34. 2010
    ..The aim of this study was to investigate the feasibility and efficacy of induction chemotherapy with gemcitabine and S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer...
  3. ncbi Prognostic factors in patients with gemcitabine-refractory pancreatic cancer
    Kohei Nakachi
    Division of Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Jpn J Clin Oncol 37:114-20. 2007
    ..The purpose of this study was to identify prognostic factors in patients with gemcitabine-refractory pancreatic cancer and to determine criteria for selecting candidates for second-line treatment...
  4. pmc Guidelines for chemotherapy of biliary tract and ampullary carcinomas
    Junji Furuse
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital East, Kashiwa shi, Chiba, Japan
    J Hepatobiliary Pancreat Surg 15:55-62. 2008
    ..It is recommended that further clinical trials, especially large multi-institutional RCTs (phase III studies) using novel agents such as gemcitabine should be performed as soon as possible in order to establish a standard treatment...
  5. ncbi [Chemotherapy]
    Masafumi Ikeda
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Gan To Kagaku Ryoho 37:408-12. 2010
    ..After the introduction of sorafenib, chemotherapy for advanced hepatocellular carcinoma has been changing remarkably, and further improvements of chemotherapy for hepatocellular carcinoma are expected...
  6. pmc Stenting and interventional radiology for obstructive jaundice in patients with unresectable biliary tract carcinomas
    Toshio Tsuyuguchi
    Department of Medicine and Clinical Oncology, Chiba University Graduate School of Medicine, Chiba, Japan
    J Hepatobiliary Pancreat Surg 15:69-73. 2008
    ..In spite of these shortcomings, evidence is expected to demonstrate its superiority over other types of stent...
  7. doi Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma
    Junji Furuse
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital East, Kashiwa, Japan
    Cancer Sci 101:2606-11. 2010
    ..In conclusion, S-1 showed an acceptable toxicity profile and promising antitumor activity for hepatocellular carcinoma, warranting further evaluation in randomized clinical trials...
  8. ncbi Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer
    Junji Furuse
    National Cancer Center Hospital East, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 36:552-6. 2006
    ..The purpose of this study was to evaluate the efficacy and toxicity of a combination chemotherapy of uracil-tegafur (UFT) and doxorubicin in patients with unresectable advanced biliary tract cancer...
  9. doi Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization
    Satoru Iwasa
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 41:770-5. 2011
    ....
  10. ncbi A phase I study of hypofractionated radiotherapy followed by systemic chemotherapy with full-dose gemcitabine in patients with unresectable locally advanced pancreatic cancer
    Junji Furuse
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, Japan
    Hepatogastroenterology 54:1575-8. 2007
    ..The purpose of this study was to determine the feasible dose of hypofractionated radiotherapy that could be followed by full-dose gemcitabine in patients with locally advanced pancreatic cancer...
  11. doi Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival
    Yu Sawada
    Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Clin Cancer Res 18:3686-96. 2012
    ..In this nonrandomized, open-label, phase I clinical trial, we analyzed the safety and efficacy of GPC3 peptide vaccination in patients with advanced HCC...
  12. doi Dose-volume histogram analysis of the safety of proton beam therapy for unresectable hepatocellular carcinoma
    Mitsuhiko Kawashima
    Division of Particle Therapy and Radiation Oncology, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Int J Radiat Oncol Biol Phys 79:1479-86. 2011
    ..To evaluate the safety and efficacy of radiotherapy using proton beam (PRT) for unresectable hepatocellular carcinoma...
  13. doi Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment
    Shinichiro Takahashi
    Department of Hepatobiliary Pancreatic Surgery, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba, 277 8577, Japan
    J Hepatobiliary Pancreat Sci 18:567-74. 2011
    ..However, few reports are available on differences in tumor characteristics and prognoses among resectable pancreatic cancer (PC), BRPC, and unresectable PC...
  14. ncbi Hepatectomy for hepatocellular carcinoma patients who meet the Milan criteria
    Hiroshi Ishii
    Division of Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan
    Hepatogastroenterology 55:621-6. 2008
    ..Although hepatocellular carcinoma patients who meet the Milan criteria are optimal candidates for liver transplantation, most such patients in Japan have been treated without liver transplantation...
  15. ncbi Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer
    Junji Furuse
    Division of Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277 8577, Japan
    Jpn J Clin Oncol 35:733-8. 2005
    ..The purpose of this study was to determine the feasible dose of gemcitabine when administered as a fixed dose rate infusion (10 mg/m(2)/min) on a weekly schedule to Japanese patients with unresectable advanced pancreatic cancer...
  16. doi Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes
    Daisuke Nobuoka
    Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Int J Oncol 40:63-70. 2012
    ..Combined treatment of RFA and immunotherapy is a reasonable strategy against HCC...
  17. ncbi Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
    Junji Furuse
    Division of Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Cancer Sci 99:159-65. 2008
    ..Moreover, promising preliminary antitumor activity has been observed. Finally, there were no clinically relevant differences in PK between Child-Pugh A and B patients...
  18. doi A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo 104 0045, Japan
    Cancer Chemother Pharmacol 63:313-9. 2009
    ..5% in chemo-naïve patients with pancreatic cancer. This study evaluated the efficacy and toxicity of S-1 in patients with gemcitabine-refractory metastatic pancreatic cancer...
  19. ncbi A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer
    Hideki Ueno
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Oncology 69:421-7. 2005
    ..The aim of this study was to determine the maximum-tolerated dose and dose-limiting toxicity (DLT) of combination therapy with gemcitabine and S-1 in patients with advanced pancreatic cancer...
  20. doi Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer
    Takuji Okusaka
    National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 102:425-31. 2011
    ..3% and 50.0%, respectively. In Japanese patients with unresectable pancreatic cancer, erlotinib plus gemcitabine had acceptable toxicity and efficacy that was not inferior to that seen in Western patients...
  21. doi Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer
    Akira Imoto
    Pathology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Int J Cancer 131:2795-807. 2012
    ..These data provide the first evidence that N-inv induces cachexia via astrocytic activation of neural route in pancreatic cancer...
  22. pmc Risk factors for biliary tract and ampullary carcinomas and prophylactic surgery for these factors
    Masaru Miyazaki
    Department of General Surgery, Chiba University Graduate School of Medicine, Chiba, Japan
    J Hepatobiliary Pancreat Surg 15:15-24. 2008
    ..This article discusses the risk factors for cancerous and precancerous lesions of the biliary tract and prophylactic treatment for these factors...
  23. ncbi [Treatments of pancreatic cancer from the standpoint of medical oncology]
    Junji Furuse
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
    Gan To Kagaku Ryoho 34:997-1001. 2007
    ..Furthermore, second-line chemotherapy regimens for use after GEM chemotherapy should be investigated to improve the survival of patients with advanced pancreatic cancer...
  24. ncbi [Unresectable gallbladder cancer with lymph node and liver metastases completely responding to S-1 monotherapy - a case report]
    Junji Furuse
    Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
    Gan To Kagaku Ryoho 34:1679-82. 2007
    ..Grade 2 anorexia, diarrhea, hand-foot skin reaction, and tasty disturbance were observed, but no grade 3 or more toxicities were noted. S-1 appeared to be effective against advanced gallbladder cancer and showed excellent tolerability...
  25. pmc Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment
    Satoshi Kondo
    Department of Surgical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    J Hepatobiliary Pancreat Surg 15:41-54. 2008
    ..The prognostic factors after resection for ampullary carcinoma include lymph node metastasis, pancreatic invasion, and perineural invasion...
  26. pmc Purpose, use, and preparation of clinical practice guidelines for the management of biliary tract and ampullary carcinomas
    Tadahiro Takada
    Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
    J Hepatobiliary Pancreat Surg 15:2-6. 2008
    ..The grading of the recommendations is based on the determination of the level of evidence in references on which the recommendation is based...
  27. pmc Flowcharts for the management of biliary tract and ampullary carcinomas
    Shuichi Miyakawa
    Department of Gastroenterological Surgery, Fujita Health University, Kutsukake cho, Toyoake, Aichi, Japan
    J Hepatobiliary Pancreat Surg 15:7-14. 2008
    ..In those with nonresectable disease, biliary stenting, chemotherapy, radiotherapy, and/or best supportive care is selected...
  28. pmc Preoperative biliary drainage for biliary tract and ampullary carcinomas
    Masato Nagino
    Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
    J Hepatobiliary Pancreat Surg 15:25-30. 2008
    ..Thus, preoperative bile replacement in patients with external biliary drainage is very likely to be effective when highly invasive surgery (e.g., extended hepatectomy for hilar cholangiocarcinoma) is planned...
  29. pmc Diagnosis of biliary tract and ampullary carcinomas
    Kazuhiro Tsukada
    Department of Surgery and Science, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, 2630 Sugitani, Toyama 930 0194, Japan
    J Hepatobiliary Pancreat Surg 15:31-40. 2008
    ..However, direct biliary tract imaging is necessary for making a precise diagnosis of the horizontal extension of bile duct cancer...
  30. pmc Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas
    Hiroya Saito
    Department of Radiology, Asahikawa Kosei General Hospital, Asahikawa 078 8211, Japan
    J Hepatobiliary Pancreat Surg 15:63-8. 2008
    ..Results from large RCTs are desired...